The project will involve: The selection of a limited number of advanced bioceramic materials (apatite containing bioceramics, calcium phosphate and calcium sulphate based materials, mesoporous bioactive glasses and borosilicate glasses) that have potential to create high added value biomedical products for the SME partners. The development of advanced high added value medical devices that offer improved and controlled biological interaction, and become part of the biological system. Research to modify and adapt the advanced bioceramic materials for new production processes, suitable for future in-hospital or in-clinic manufacture of personalised devices. Full assessment of the new bioceramic materials and devices, on the grounds of potential clinical effectiveness, economics, and environmental impact.
Leitat’s role in the project: LEITAT will lead WPs 10 and 12, and contribute to WPs 7, 8 and 9. LEITAT will perform life-cycle costing and environmental analysis within WP10, and will manage the dissemination and exploitation activities through WP12. LEITAT will contribute design and analysis expertise to WP’s 7, 8, and 9.
Number of Contract: FP7/280575
Coordinator: University of Newcastle
Email LEITAT manager in charge: Izabel Alfany
Duration: 48 months
|University of Newcastle upon Tyne||UK|
|Sagetis Biotech SL||Spain|
|Orla Protein technologies Ltd||UK|
|LEITAT Technological Center||Spain|
|Universidade de Evora||Portugal|
|Glass Technology Services Limited||UK|
|Institut Químic de Sarrià||Spain|
|Fondazione del Piemonte per l’Oncologia||Italy|
|Joint Replacement Instrumentation Limited||UK|